A detailed history of Kellner Capital, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Kellner Capital, LLC holds 20,300 shares of CERE stock, worth $0. This represents 1.55% of its overall portfolio holdings.

Number of Shares
20,300
Holding current value
$0
% of portfolio
1.55%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024

BUY
$20.27 - $42.44 $411,481 - $861,532
20,300 New
20,300 $861,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Kellner Capital, LLC Portfolio

Follow Kellner Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kellner Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kellner Capital, LLC with notifications on news.